menu
    • menu
    [{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ADU-1604","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Sairopa","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"}]

    Find Clinical Drug Pipeline Developments & Deals by Sairopa

    Menu

    Sairopa

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sairopa

                            Netherlands arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Sairopa

                            Netherlands arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADU-1604

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Exelixis

                            Deal Size : $335.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sairopa and Exelixis Achieve $35M From Milestones in 2024 Partnership

                            Details : The collaboration combines Exelixis' proven oncology drug development and commercialization track record with Sairopa's expertise. ADU-1805 is currently being evaluated for melanoma.

                            Product Name : ADU-1604

                            Product Type : Other Large Molecule

                            Upfront Cash : $40.0 million

                            December 17, 2024

                            Lead Product(s) : ADU-1604

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Exelixis

                            Deal Size : $335.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sairopa

                            Netherlands arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Sairopa

                            Netherlands arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADU-1805

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with...

                            Details : ADU-1805 is a monoclonal antibody which blocks SIRPα, a significant immune-suppressive component of the tumor microenvironment which leads in improved immune system’s ability to attack tumors.

                            Product Name : ADU-1805

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : ADU-1805

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sairopa

                            Netherlands arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Sairopa

                            Netherlands arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADU-1805

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Exelixis

                            Deal Size : $335.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop AD...

                            Details : Exelixis and Sairopa will develop ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα. ADU-1805 is active against all human alleles of SIRPα, which may allow it to address a broader patient population than other SIRPα-directed...

                            Product Name : ADU-1805

                            Product Type : Antibody

                            Upfront Cash : $40.0 million

                            January 11, 2022

                            Lead Product(s) : ADU-1805

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Exelixis

                            Deal Size : $335.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth